1,2-Dimethoxybenzene

1,2-Dimethoxybenzene

SCHEMBL4624077

COc1ccccc1OC.OB(O)O

nearest known ligand 0.77

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 4/20 0.77
CA2 P00918 4/20 0.77
CA7 P43166 3/20 0.77
CA9 Q16790 3/20 0.77
CA12 O43570 2/20 0.77
CA14 Q9ULX7 2/20 0.77
CA4 P22748 1/20 0.77
ENPP2 Q13822 1/20 0.68
ORAI1 Q96D31 1/20 0.65
ORAI2 Q96SN7 1/20 0.65
ORAI3 Q9BRQ5 1/20 0.65
TP53 P04637 2/20 0.59
TSHR P16473 1/20 0.59
ALDH1A1 P00352 3/20 0.56
MAPK1 P28482 2/20 0.56
HTT P42858 2/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
ADRA2B P18089 1/20 0.52
PTGS1 P23219 1/20 0.52
TDP1 Q9NUW8 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
1,2-Dimethoxybenzene SCHEMBL27977851 0.88 CA1 (0.59) CA1CA2CA7CA9CA12
1,2-Dimethoxybenzene SCHEMBL27891985 0.88 CA1 (0.87) CA1CA2CA7CA9CA12
1,2-Dimethoxybenzene SCHEMBL105872 0.87 CA1 (1.00) CA1CA2CA7CA9CA12
1,2-Dimethoxybenzene SCHEMBL5308636 0.87 CA1 (1.00) CA1CA2CA7CA9CA12
1,2-Dimethoxybenzene SCHEMBL29351917 0.87 CA1 (1.00) CA1CA2CA7CA9CA12
SCHEMBL30689248 0.85 CA1 (0.62) CA1CA2CA7CA9CA12
SCHEMBL2260419 0.85 CA1 (0.62) CA1CA2CA7CA9CA12
1,2-Dimethoxybenzene SCHEMBL9793057 0.84 CA1 (0.93) CA1CA2CA7CA9CA12
1,2-Dimethoxybenzene SCHEMBL28602492 0.84 CA1 (0.93) CA1CA2CA7CA9CA12
1,2-Dimethoxybenzene SCHEMBL29229370 0.84 CA1 (0.93) CA1CA2CA7CA9CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0971878-B1 AMINE COMPOUNDS, THEIR PRODUCTION AND USE AS AMYLOID-BETA PRODUCTION INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2008-03-26 EP disclosed
US-7256204-B2 Amine compounds, their production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-08-14 US disclosed
US-20040077867-A1 Amine compounds, their production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-04-22 US disclosed
US-6613805-B2 For therapy and prophylaxis of neurodegenerative diseases such as Alzheimer's disease, Down's syndrome, Parkinson's disease, Creutzfeldt-Jacob disease, amyotrophic sclerosis on lateral fasciculus, multiple sclerosis, and neurological disorders TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-09-02 US disclosed
US-20020032189-A1 For therapy and prophylaxis of neurodegenerative diseases such as Alzheimer's disease, Down's syndrome, Parkinson's disease, Creutzfeldt-Jacob disease, amyotrophic sclerosis on lateral fasciculus, multiple sclerosis, and neurological disorders THE UNIVERSITY OF TOKYO (JP) 2002-03-14 US disclosed
US-6310107-B1 (+)-6-(4-BIPHENYLYL)METHOXY-2-(2-(N,N-DIMETHYLAMINO)ETHYL)TETR ALIN, OR A SALT IS USEFUL FOR INHIBITING PRODUCTION AND/OR SECRETION OF AMYLOID-BETA PROTEIN TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-10-30 US disclosed
EP-0971878-A1 AMINE COMPOUNDS, THEIR PRODUCTION AND USE AS AMYLOID-BETA PRODUCTION INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2000-01-19 EP disclosed
WO-1998038156-A1 AMINE COMPOUNDS, THEIR PRODUCTION AND USE AS AMYLOID-BETA PRODUCTION INHIBITORS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1998-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020032189-A1 For therapy and prophylaxis of neurodegenerative diseases such as Alzheimer's disease, Down's syndrome, Parkinson's disease, Creutzfeldt-Jacob disease, amyotrophic sclerosis on lateral fasciculus, multiple sclerosis, and neurological disorders PARK7, PSEN1, PRNP CA1 3139/4885CA2 3174/4885CA7 3997/4885
US-20040077867-A1 Amine compounds, their production and use QSOX1, APP, NPR1 CA1 1187/4885CA2 1498/4885CA7 1948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.